These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 1358265

  • 1. Untoward reactions to gastric antisecretory drugs.
    Bertaccini G, Coruzzi G.
    Ital J Gastroenterol; 1992 Oct; 24(8):470-1. PubMed ID: 1358265
    [No Abstract] [Full Text] [Related]

  • 2. [What is the role of H2 receptor blockers today in ulcer therapy?].
    Creutzfeldt W.
    Internist (Berl); 1996 Sep; 37(9):937-8. PubMed ID: 8964690
    [No Abstract] [Full Text] [Related]

  • 3. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole.
    Källén B.
    Br J Obstet Gynaecol; 1998 Aug; 105(8):877-81. PubMed ID: 9746381
    [Abstract] [Full Text] [Related]

  • 4. [The interaction potential of H2 receptor antagonists. A short current review].
    Klotz U, Kroemer HK.
    Fortschr Med; 1991 Sep 30; 109(28):574-6. PubMed ID: 1684557
    [No Abstract] [Full Text] [Related]

  • 5. Omeprazole, H2 blockers, and polyarthralgia: case-control study.
    Meier CR, Jick H.
    BMJ; 1997 Nov 15; 315(7118):1283. PubMed ID: 9390057
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study.
    Neal KR, Scott HM, Slack RC, Logan RF.
    BMJ; 1996 Feb 17; 312(7028):414-5. PubMed ID: 8601113
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C.
    Clin Ther; 1993 Feb 17; 15 Suppl B():14-21. PubMed ID: 7911399
    [Abstract] [Full Text] [Related]

  • 15. Safety profile of H2-receptor antagonists: current status of famotidine.
    Levine JB.
    J Int Med Res; 1989 Feb 17; 17 Suppl 1():48A-53A. PubMed ID: 2566543
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
    Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A, Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP).
    Pediatrics; 2006 May 17; 117(5):e817-20. PubMed ID: 16651285
    [Abstract] [Full Text] [Related]

  • 20. The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach.
    Wang K, Lin HJ, Perng CL, Tseng GY, Yu KW, Chang FY, Lee SD.
    Hepatogastroenterology; 2004 May 17; 51(59):1540-3. PubMed ID: 15362796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.